Rosenberg, Ari J.
Izumchenko, Evgeny
Pearson, Alexander
Gooi, Zhen
Blair, Elizabeth
Karrison, Theodore
Juloori, Aditya
Ginat, Daniel
Cipriani, Nicole
Lingen, Mark
Sloane, Hillary
Edelstein, Daniel L.
Keyser, Kirsten
Fredebohm, Johannes
Holtrup, Frank
Jones, Frederick S.
Haraf, Daniel
Agrawal, Nishant
Vokes, Everett E.
Funding for this research was provided by:
American Cancer Society (IRG-19-136-59)
Article History
Received: 27 November 2021
Accepted: 23 December 2021
First Online: 3 January 2022
Declarations
:
: This study protocol was approved by the University of Chicago Institutional Review Board (UCCCC IRB Number 20–0713). All patients provide written informed consent prior to enrollment.
: Not applicable.
: AJR reports research support paid to the institution: Merck, BMS, Celgene; Consulting/Scientific Advisory Board: Nanobiotix, EMD-Serono. AP serves on advisory board for Prelude Therapeutics. AJ reports research funding from AstraZeneca. EEV reports consultant/advisory roles for AbbVie, AstraZeneca, Beigene, BioNTech, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, Merck, and Novartis. Other authors report no conflicts of interest.